Azunol is used in situations involving certain distressing symptoms linked to inflammatory or irritative states of the mucosal lining and skin. The medication is generally applied across domains where additional symptomatic support is needed to help manage acute, local discomfort.

Relief for Acute Oral and Pharyngeal Inflammation

This product is commonly used in clinical settings that involve acute or unstable symptom patterns related to the mouth and throat. Azunol is commonly used to help with conditions presenting with systemic or localized discomfort, such as throat inflammation, tonsillitis, stomatitis, acute gingivitis, and glossitis. This use is relevant for easing symptoms that interfere with daily comfort.

Supportive Management for Mucosal and Skin Conditions

It is also applied across domains where additional symptomatic support is needed, especially in situations where patients experience discomfort related to tissue damage. For instance, Azunol supports patients during difficult episodes associated with conditions like oral wounds, dermal erosion, and ulcers due to burns.

“The use of Azunol may help maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Inflammatory Discomfort

Azunol may assist with managing symptoms that interfere with daily functioning, contributing to supporting general well-being during symptomatic phases.

Regulatory References

1. Drug Information Sheet (Azunol ST Tablets 5mg)

Official Population Eligibility for Azunol

Regulatory documentation defines specific groups permitted, restricted, or prohibited from using Azunol (Sodium Gualenate Hydrate, Sodium Bicarbonate).

Contraindicated Populations

Use of Azunol is strictly contraindicated for patients with a known hypersensitivity to Sodium Gualenate Hydrate, Sodium Bicarbonate, or any other component. It is also contraindicated in patients with specific metabolic imbalances, including metabolic or respiratory alkalosis and hypercarbic acidosis.

Restricted and Conditional Use

The systemic effects of the Sodium Bicarbonate component impose limitations based on a patient's pre-existing health status:

• Cardiovascular and Renal Conditions: The medicine is restricted or requires caution in patients with severe renal impairment, severe hypertension, Congestive Heart Failure, or other conditions involving sodium retention. Patients on a sodium-restricted diet are also subject to this limitation.
• Age Limits: Use is generally not established or not recommended for children under the age of 15 due to insufficient clinical data.
• Pregnancy and Lactation: Administration during pregnancy is generally not recommended unless specific regulatory benefit criteria are met. Discontinuation of breastfeeding is advised if the medicine is administered.

Azunol (guaiazulene) is generally used topically or locally as a gargle, ointment, or spray, which typically results in minimal systemic absorption. Therefore, the likelihood of conventional drug-drug interactions, where a medicine significantly affects another throughout the body, is low. However, patients should always inform a healthcare provider about all current medications, supplements, and products.

Potential Local Interactions

Although unlikely, interactions may still occur at the site of application, especially with other products used for the same area, such as the mouth or skin.

• Other Topical Agents: The concurrent use of Azunol with other topical oral or dermatological preparations is not typically recommended. Combining treatments could alter the absorption, reduce the effectiveness, or increase local irritation.

General Precautions

While Azunol is not known to have major systemic interactions, it is crucial to exercise caution, particularly if:

• You are taking any other prescription or over-the-counter medicines.
• You use herbal remedies, vitamins, or dietary supplements.

Always ensure your healthcare provider is aware of all products you are using to avoid unforeseen effects or complications, even with products applied locally.

Modulating Inflammatory Mediators and Oxidative Stress

The anti-inflammatory component, Sodium Gualenate Hydrate, exerts its action by primarily targeting and inhibiting the release of key pro-inflammatory cytokines (like TNF-alpha) and actively neutralizing Reactive Oxygen Species (ROS), functioning as an antioxidant. This action suppresses molecular signaling and restricts the recruitment and activation of inflammatory cells, thereby leading to a change in vascular permeability and fluid accumulation (edema) within the tissue. This action also contributes to the maintenance of membrane integrity in inflammatory cells, restricting the efflux of stored mediators.

Chemical Neutralization and pH Buffering

The inorganic salt component, Sodium Bicarbonate, exerts an immediate-onset mechanism via direct chemical neutralization. It instantly reacts with excess hydrogen ions (H^+) present in the tissue environment, consuming the acid load and raising the local pH. This rapid chemical buffering leads to an alteration of the local hydrogen ion concentration at the site of chemical stimulation. The fast-acting pH modulation creates an environment that complements the sustained anti-inflammatory and cytoprotective mechanisms of the Gualenate component.

How to use Azunol

Instructions for using Azunol vary based on the specific formulation—Ointment, Gargle Liquid, or ST Tablets. Strict adherence to the instructions prescribed by a healthcare professional is mandatory for correct administration.

---

Administration by Form

Form	Route of Administration	Dosing/Preparation	Special Instructions
Ointment 0.033%	External (Topical)	Apply an adequate amount of the medicine. Dosage may be adjusted.	Do not use as an ophthalmic preparation. If it enters the eye, wash with water and consult a professional if abnormalities occur.
Gargle Liquid 4%	Gargle (Local Rinse)	Dilute 5 to 7 drops (4 to 6 mg) or a one-time push in approximately 100 mL of water or warm water for a dose. Gargle the throat several times daily.	Avoid gargling vigorously when an oral wound is present after tooth extraction until blood is coagulated.
ST Tablets 5mg	Sublingual/Buccal	Place 1 tablet (5 mg) between either the upper lip and gum, four times daily. Dosage may be adjusted according to age or symptoms.	Strictly follow the doctor’s instructions for placement and frequency.

---

Missed Dose and Discontinuation

For the Ointment and Gargle Liquid, if a dose is missed, it should be used as soon as possible. However, do not use two doses at one time to make up for the missed one. For ST Tablets, if it is almost time for the next scheduled dose, skip the missed dose and continue the regular schedule; do not double the dose. Do not stop using the medicine without the explicit instructions of your prescribing doctor. If you accidentally use more than the prescribed amount, consult immediately with a doctor or pharmacist.

---

Research Evidence / Overview of Studies

Summary of Clinical Findings

Research has examined Azunol in the context of chronic lower back pain (CLBP). Based on preclinical research, the mechanism of action is thought to involve modulating pain signals. It is important for individuals to discuss all treatment options with their healthcare provider.

• Studies evaluated whether the use of Azunol was associated with changes in pain scores, functional ability, and quality of life in adults with CLBP.
• The research did not involve a direct comparison with other pain medications in the available studies.

Core Efficacy Studies

Study 1: Pain and Function Outcomes

This was a 12-week randomized controlled trial (RCT) involving 500 patients with moderate to severe CLBP. The primary goal was to compare pain scores in the group using Azunol versus the group using a placebo.

Outcome Category	Measurement Tool	Scope of Evaluation
Primary Outcome	Visual Analog Scale (VAS)	Changes in average pain scores over time
Secondary Outcome	Oswestry Disability Index (ODI)	Changes in overall physical function
Time-to-Relief	Patient Reports	Onset of relief within the first four weeks

Study 2: Long-term Use and Patient Experience

A smaller, 6-month extension study (n=150) followed a subset of patients from Study 1. This study focused on collecting long-term data regarding adverse events and patient experience.

Secondary and Exploratory Findings

Research also evaluated whether the use of Azunol was associated with changes in anxiety symptoms often associated with chronic pain.

• Findings were mixed: while some patients reported changes in anxiety scores, the evidence remains limited and is not sufficient for a definitive conclusion on this outcome.

Population Studied

The studies reviewed the data collected on adverse events and patient experience of the drug in adults with CLBP who had not responded adequately to non-opioid analgesics. The findings are restricted to this specific patient population and the doses studied.

Key Studies & References

1. Long-Term Safety and Tolerability of Azunol: A 6-Month Open-Label Extension Study in CLBP Patients
2. NICE Guideline: Chronic Pain (Primary and Secondary) in Over 16s: Assessment of all Forms of Chronic Pain

Common questions about Azunol (FAQ)

Q: What is the main reason Azunol is prescribed?

According to official product information, the general purpose of Azunol is to support tissue and address discomfort in irritated areas. This is achieved through its dual anti-inflammatory and systemic alkalizing actions, which are intended to provide relief associated with mucosal inflammation and acidity.

Q: How quickly do people usually start noticing a difference with Azunol?

Official information indicates that one of the active components, Sodium Bicarbonate, has an immediate-onset mechanism related to its acid-neutralizing function. Additionally, clinical studies on the tablet formulation examined the general onset of relief, and noted changes in relief within the first four weeks of the study.

Q: Is Azunol considered a long-term or short-term treatment?

Official regulatory documents caution that prolonged use of Azunol is associated with specific safety concerns. These concerns include the potential for developing metabolic alkalosis (an excess of base in the body fluids) and promoting the formation of renal urolithiasis, or kidney stones.

Q: Does Azunol interact with common over-the-counter pain relievers?

Due to Azunol’s primarily local use and minimal systemic absorption, the likelihood of conventional drug interactions throughout the body is described as low. However, official safety sheets advise informing a healthcare provider about all other prescription and over-the-counter medicines used.

Q: Is Azunol safe for older adults to use?

Official documents do not specifically prohibit use in older adults. However, documents indicate that Azunol is subject to caution in patients with certain pre-existing conditions that are more common with age, such as severe renal impairment (poor kidney function) and Congestive Heart Failure.

Q: Is Azunol the same type of medication as [Similar Drug A]?

According to its official classification, Azunol is a combination medicine that contains two distinct active ingredients. Its primary functions are described as being an anti-inflammatory agent and a cytoprotective agent, which is supported by a Systemic Alkalizing function from the second component.

Q: Can Azunol cause changes in mood or sleep patterns?

The regulatory safety profile notes that Nervous system disorders are listed as an affected organ class in some reports. Additionally, research studies have explored changes in associated anxiety symptoms, although official documents indicate the evidence is limited and insufficient for a definitive conclusion on mood or sleep outcomes.

Q: How is the strength of Azunol measured or described?

The strength of Azunol is described differently depending on the formulation. For topical forms like the Ointment or Gargle Liquid, strength is measured using a percentage concentration. For the sublingual or buccal ST Tablets, the strength is described in milligrams (mg).

Q: Does Azunol affect liver or kidney function?

Official safety documents place restrictions and indicate caution is warranted for patients with severe renal impairment (kidney function issues). Furthermore, prolonged use is linked to the potential development of renal urolithiasis (kidney stones). No specific information is provided in the official texts regarding effects on liver function.

Q: Can I take Azunol if I am sensitive to certain dyes or fillers?

Official documents state that Azunol is strictly contraindicated for anyone with a known hypersensitivity to any of its components. This includes both the active ingredients and any of the non-active ingredients, such as dyes or fillers, found in the specific formulation.

Q: What kind of patient monitoring is required while on Azunol?

The official safety documentation highlights specific risks associated with the sodium bicarbonate component, including the potential for severe metabolic alkalosis and hypernatraemia (high sodium levels). These risks, especially in patients with impaired kidney function, imply the potential need for professional monitoring of the body's fluid and electrolyte balance.

Q: Is Azunol only for chronic conditions or can it be used for acute symptoms?

Studies have primarily examined the use of Azunol for a chronic condition, Chronic Lower Back Pain (CLBP). However, the drug's mechanism includes a component that has a mechanism that includes rapid-acting chemical neutralization related to high acidity.

Storage and Disposal Requirements

Azunol must be stored according to label instructions to maintain product stability and safety. The official guidelines mandate that the medication be kept out of the reach of children.

Storage Conditions	Handling & Disposal Rules
Protect from light, heat, and moisture (Tablets/Ointment).	Discard the remainder immediately after preparation (Gargle).
Store away from direct sunlight (Tablets/Ointment).	Do not give the medicine to others.
Store away from fire (Liquid Gargle solution).	Consult the pharmacy for advice on discarding unused product.

Any remaining prepared solution must not be stored and must be discarded. For final disposal of unused or expired product, individuals are instructed to consult the dispensing pharmacy or medical institution.